# US 2023/0235327 A1 · A dbait molecule in combination with kras inhibitor for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0235327 A1
- Document ID: US20230235327A1
- Status: Published application
- Kind: A1
- Application number: 18/007,768
- Filed: 2021-06-04
- Published: 2023-07-27
- Earliest claimed: 2020-06-05
- Assignees: Onxeo
- Applicants: Onxeo
- Inventors: WAEL JDEY; FRANÇOISE BONO
- Web page: https://patentgrep.com/patent/US20230235327A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 2310/13: Decoys
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/31: Combination therapy
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the combination of a Dbait molecule with a KRAS inhibitor for treating cancer.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A pharmaceutical composition comprising a Dbait molecule and a protein KRAS inhibitor, wherein the Dbait molecule has one of the following formulae:
wherein N is a deoxynucleotide, n is an integer from 15 to 195, the underlined N refers to a nucleotide having or not a modified phosphodiester backbone, L′ is a linker, C is the molecule facilitating endocytosis selected from a lipophilic molecule or a ligand which targets cell receptor enabling receptor mediated endocytosis, L is a linker, m and p, independently, are an integer being 0 or 1.

### Claim 18 (depends on 17)

The pharmaceutical composition according to claim 17, wherein the Dbait molecule has the following formula:

### Claim 19 (depends on 17)

The pharmaceutical composition according to claim 17, wherein the KRAS inhibitor is a direct KRAS inhibitor selected from the group consisting of specific covalent KRAS inhibitors and multivalent small-molecule pan KRAS inhibitors.

### Claim 20 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the KRAS inhibitor is selected from the group consisting of AMG-510/sotorasib (Amgen/Carmot Therapeutics), MRTX-849/Adagrasib (Mirati Therapeutics), ARS-3248/JNJ-74699157 (Johnson & Johnson/Wellspring Biosciences), Compound B (Sanofi/X-Chem Pharmaceuticals), LY3499446 (Eli Lilly), ARS-853, ARS-1620, BI-2852, BI-1701963 (Boehringer Ingelheim), mRNA-5671 (Moderna Therapeutics), G12D inhibitor (Mirati), RAS(On)inhibitors (Revolution medicines), and BBP-454 (BridgeBio Pharma).

### Claim 21 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the KRAS inhibitor is a KRASG12C inhibitor directly targeting and binding mutant KRASG12C protein.

### Claim 22 (depends on 17)

The pharmaceutical composition according to claim 17, wherein the KRAS inhibitor leaves wild-type KRAS protein untouched.

### Claim 23

A combination comprising a Dbait molecule and a protein KRAS inhibitor, wherein the Dbait molecule has one of the following formulae:
wherein N is a deoxynucleotide, n is an integer from 15 to 195, the underlined N refers to a nucleotide having or not a modified phosphodiester backbone, L′ is a linker, C is the molecule facilitating endocytosis selected from a lipophilic molecule or a ligand which targets cell receptor enabling receptor mediated endocytosis, L is a linker, m and p, independently, are an integer being 0 or 1.

### Claim 24 (depends on 23)

The combination according to claim 23, wherein the Dbait molecule has the following formula:

### Claim 25 (depends on 23)

The combination according to claim 23, wherein the KRAS inhibitor is a direct KRAS inhibitor selected from the group consisting of specific covalent KRAS inhibitors and multivalent small-molecule pan KRAS inhibitors.

### Claim 26 (depends on 25)

The combination according to claim 25, wherein the KRAS inhibitor is selected from the group consisting of AMG-510/sotorasib (Amgen/Carmot Therapeutics), MRTX-849/Adagrasib (Mirati Therapeutics), ARS-3248/JNJ-74699157 (Johnson & Johnson/Wellspring Biosciences), Compound B (Sanofi/X-Chem Pharmaceuticals), LY3499446 (Eli Lilly), ARS-853, ARS-1620, BI-2852, BI-1701963 (Boehringer Ingelheim), mRNA-5671 (Moderna Therapeutics), G12D inhibitor (Mirati), RAS(On)inhibitors (Revolution medicines), and BBP-454 (BridgeBio Pharma).

### Claim 27 (depends on 25)

The combination according to claim 25, wherein the KRAS inhibitor is a KRASG12C inhibitor directly targeting and binding mutant KRASG12C protein.

### Claim 28 (depends on 25)

The combination according to claim 25, wherein the KRAS inhibitor leaves wild-type KRAS protein untouched.

### Claim 29 (depends on 23)

A method of treating cancer comprising administering a pharmaceutical composition according to claim 23 to a subject in need of treatment.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the cancer is a cancer driven by a KRAS mutation selected from the group consisting of KRASG12C, KRASG12V, KRASG12S, KRASG12D, KRASG13C, KRASG13D, KRASG12C, and KRASG12D.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the cancer is selected from the group consisting of a cancer of head and neck, pancreas, stomach, colon, colorectum, small intestine, biliary tract, kidney, ovary, prostate, thyroid, esophagus, breast, bladder, lung, liver, uterine corpus, endometrium, cervix, urinary tract, peritoneal cancers, multiple myeloma, sarcoma, skin cancer, melanoma, uveal melanoma, and hematopoietic cancers.

### Claim 32 (depends on 23)

A method of treating cancer comprising administering a therapeutically effective amount of a combination according to claim 23 to a subject in need of treatment.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the cancer is a cancer driven by a KRAS mutation selected from the group consisting of KRASG12C, KRASG12V, KRASG12S, KRASG12D, KRASG13C, KRASG13D, KRASG12C, and KRASG12D.

### Claim 34 (depends on 32)

The method according to claim 32, wherein the cancer is selected from the group consisting of a cancer of head and neck, pancreas, stomach, colon, colorectum, small intestine, biliary tract, kidney, ovary, prostate, thyroid, esophagus, breast, bladder, lung, liver, uterine corpus, endometrium, cervix, urinary tract, peritoneal cancers, multiple myeloma, sarcoma, skin cancer, melanoma, uveal melanoma, and hematopoietic cancers.

### Claim 35 (depends on 17)

A method of delaying the development of a cancer resistant to a KRAS inhibitor in a patient comprising administering a composition according to claim 17 to a patient in need of treatment.

### Claim 36 (depends on 23)

A method of delaying the development of a cancer resistant to a KRAS inhibitor in a patient comprising administering a combination according to claim 23 to a patient in need of treatment.

### Claim 37 (depends on 17)

A method of treating cancer persister cells is a subject having cancer comprising administering a composition according to claim 17 to said subject.

### Claim 38 (depends on 23)

A method of treating cancer persister cells is a subject having cancer comprising administering a combination according to claim 23 to said subject.
